Published in final edited form as:

J Acquir Immune Defic Syndr. 2013 November 1; 64(3): . doi:10.1097/QAI.0b013e3182a9213a.

HIV infection is associated with diffusing capacity impairment in women

Meghan E. Fitzpatrick, MD^{1,*}, Matthew R. Gingo, MD, MS^{1,*}, Cathy Kessinger, RN¹, Lorrie Lucht¹, Eric Kleerup, MD², Ruth M. Greenblatt, MD^{3,4,5}, David Claman, MD⁴, Claudia Ponath, MA⁴, Serena Fong⁴, Laurence Huang, MD, MAS⁴, and Alison Morris, MD, MS^{1,6}

¹Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

²Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles

³Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco

⁴Department of Medicine, School of Medicine, University of California, San Francisco

⁵Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco

⁶Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania

Abstract

Respiratory dysfunction is common in HIV, but few studies have directly assessed whether HIV remains an independent risk factor for pulmonary function abnormalities in the antiretroviral therapy era. Additionally, few studies have focused on pulmonary outcomes in HIV+ women.

We tested associations between risk factors for respiratory dysfunction and pulmonary outcomes in 63 HIV+ and 36 HIV-uninfected women enrolled in the Women's Interagency HIV Study. Diffusing capacity (DL_{CO}) was significantly lower in HIV+ women (65.5% predicted vs. 72.7% predicted, p=0.01), and self-reported dyspnea in HIV+ participants was associated with both DL_{CO} impairment and airflow obstruction. Providers should be aware that DL_{CO} impairment is common in HIV and that either DL_{CO} impairment or airflow obstruction may cause respiratory symptoms in this population.

Keywords

HIV; Pulmonary function; Pulmonary diffusing capacity; AIDS; Hepatitis C, chronic

INTRODUCTION

With combination antiretroviral therapy (ART), HIV has become a chronic disease in people with access to treatment, and new challenges have arisen in describing and managing the complications of long-term HIV infection. One emerging concern for treated HIV patients is

Corresponding Author: Alison Morris, MD, MS, 3459 Fifth Avenue, 628 NW, Pittsburgh, PA 15213, morrisa@upmc.edu, Fax: (412) 692-2260, Phone: (412) 624-8209.

*These authors contributed equally.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest: No conflicts of interest were declared.

the increased occurrence of chronic pulmonary dysfunction^{1–3}. HIV is a risk factor for both prevalent and incident diagnosis of chronic obstructive pulmonary disease (COPD)^{1, 2}. Several cross-sectional studies of pulmonary function testing (PFT) in HIV-infected cohorts have demonstrated a higher than expected prevalence of obstructive lung disease (ranging from 8–21% in mid-life adults)^{3–6} and impaired diffusing capacity for carbon monoxide (DL_{CO}) which is strikingly prevalent (64% overall and 48% of never-smokers)³. Past studies measuring DL_{CO} are limited by the absence of an HIV-uninfected control group. Whether HIV is independently associated with impaired DL_{CO} in the current era is unknown.

Pulmonary complications in HIV-infected women, who comprise approximately 25% of the HIV-infected population in the United States⁷, are understudied. Most current-era investigations examining lung function or respiratory symptoms have been primarily focused on men (66–100% male)^{1–6, 8–10}, and no studies have specifically compared pulmonary outcomes between HIV-infected and HIV-uninfected women. Characterizing pulmonary dysfunction among HIV-infected women is important since pulmonary risk behaviors are common in this group; for example, approximately 56% and 72% of HIV-infected women are current or former smokers, respectively¹¹. Additionally, sex differences occur in the natural history of lung disease; female smokers may be more susceptible to COPD than males¹². Improved understanding of the contributions of HIV infection to pulmonary outcomes and interactions between HIV and other pulmonary risk factors among females will help guide assessment, risk factor modification, and potential treatment approaches.

In this study, we assessed the effects of HIV infection on pulmonary function measures in women. We measured lung function in HIV-infected and HIV-uninfected women from a site of the Women's Interagency HIV Study (WIHS) and examined predictors of pulmonary function abnormalities and dyspnea among HIV-infected women.

METHODS

Participants

The WIHS cohort has been previously described and includes both HIV-infected women and HIV-negative controls with a similar high-risk profile and exposure history for HIV infection¹³. For this study, a subset of women were selected to match the overall cohort prevalence in HIV status, smoking history, and prevalence of respiratory symptoms in the WIHS cohort^{13, 14} at the University of California, San Francisco. This matching was performed to avoid a bias in assessing the population if, for example, more smokers or more individuals with respiratory complaints volunteered for this pulmonary study, thus biasing the results. Participants were enrolled between April 2009 and November 2011 and were excluded if there were contraindications to pulmonary function testing, they were pregnant, or they were experiencing new or increasing respiratory symptoms in the past four weeks. Participants provided written informed consent, and study protocols were approved by the University of California, San Francisco Institutional Review Board.

Data collection

Demographic and clinical data in WIHS participants are collected at 6 month standardized assessments, as previously described¹⁴. We extracted data including age, race, ethnicity, self-reported alcohol use (any amount of alcohol during the previous 6 month period, or heavy alcohol use if >3 drinks per week), illicit drug use (ever-use or use in the 6 months before the WIHS visit that preceded pulmonary function testing), use and adherence to antiretroviral drugs, and history of bacterial and *Pneumocystis* pneumonia. Hepatitis C RNA positivity results were available at entry into WIHS, and CD4 count and plasma HIV RNA

level were available from each completed 6-month visit. Current smoking status and pack-years of smoking were determined from participant report at the time of pulmonary function testing. Dyspnea was assessed using a standardized questionnaire¹⁵.

Spirometry and DL_{CO} measurements were performed per ATS/European Respiratory Society (ERS) standards and were adjusted for hemoglobin and carboxyhemoglobin^{16, 17}; reference values that adjusted for race, age, and height were used to determine percent predicted^{18, 19}. Abnormal forced expiratory volume in one second (FEV₁), forced vital capacity (FVC), and DL_{CO} were defined as <80% predicted values, and moderately severe diffusing capacity impairment was defined by a DL_{CO} <60% predicted value²⁰.

Statistical Analysis

Statistical analyses were performed using Stata version 12 (StataCorp, College Station, TX). Characteristics of participants, pulmonary function variables, and dyspnea symptoms were compared between HIV-infected and HIV-uninfected women using t-tests, rank-sum, chi-squared, or Fisher exact tests where appropriate. To determine the independent association of HIV with pulmonary function values, linear regression models were created. Variables were selected for inclusion in the models if they had a univariate association to the pulmonary function parameter with $p < 0.1$. Because spirometry and DL_{CO} prediction equations adjust for age and race, these variables were not included in these PFT models, but age and race were included in models for FEV₁/FVC ratios (which are not based on prediction equations). Multivariable model selection was done by a stepwise up/stepwise down process as previously described²¹. Excessive covariance was assessed using variance inflation factors. To assess for confounding by smoking, pack-years of smoking was added to the final models, and no significant effect was found (data not shown). To assess for HIV-related factors associated with lung function, similar modeling procedures were performed comparing HIV-infected women with CD4 counts ≥ 200 cells/ μ L and >200 cells/ μ L vs. HIV-uninfected women. Additionally, associations were modeled using data limited to HIV-infected participants including the following variables: ART use, current CD4 count, and current plasma HIV RNA copy level.

RESULTS

One hundred six WIHS participants were screened, but seven participants were not able to complete pulmonary function testing per ATS/ERS standards. Pulmonary function testing was completed by 63 HIV-infected and 36 HIV-uninfected participants (Table 1).

Spirometry

Overall, mean spirometry values were within normal limits for the cohort, and did not differ between HIV-infected and HIV-uninfected participants (Table 1). In multivariable analyses, several factors were associated with spirometry outcomes for the entire cohort (HIV-infected and HIV-uninfected) (Table 2); however, HIV was not identified as a risk factor.

Among the HIV-infected women, hepatitis C positivity was associated with lower post-bronchodilator FEV₁% predicted ($p=0.03$) and lower post-bronchodilator FVC% predicted ($p=0.04$), and history of bacterial or *Pneumocystis* pneumonia was associated with lower FEV₁/FVC, both pre- ($p=0.01$) and post-bronchodilator ($p=0.03$). Marijuana use was associated with greater pre-bronchodilator FVC% predicted ($p=0.045$) and post-bronchodilator FEV₁% predicted ($p=0.03$).

Diffusing capacity

Diffusing capacity was abnormal on average in this cohort and to a greater degree in HIV-infected compared to HIV-uninfected participants ($p=0.01$) (Table 1). Impaired diffusing capacity ($DL_{CO} < 80\%$ predicted) was present similarly in HIV-infected and HIV-uninfected participants ($p=0.27$), but moderately impaired diffusing capacity ($DL_{CO} < 60\%$ predicted) was more common in HIV-infected vs. HIV-uninfected participants ($p=0.04$). HIV-infected participants with a current CD4 count < 200 cells/ μ L had significantly worse $DL_{CO}\%$ predicted compared to HIV-uninfected women (59.5% [7.2%] vs. 72.7% [13.3%], $p<0.001$). Multivariable modeling demonstrated that worse $DL_{CO}\%$ predicted was associated with HIV infection ($p=0.03$) and hepatitis C RNA positivity ($p=0.009$) (Table 2A). Pack years of smoking did not influence DL_{CO} in this cohort. Although $DL_{CO} < 60\%$ predicted was much more likely in those with airflow obstruction ($FEV_1/FVC < 0.7$), 51.7% of participants with a $DL_{CO} < 60\%$ predicted had no evidence of airflow obstruction.

In HIV-infected participants, DL_{CO} was associated with the current CD4 cell count (unadjusted coefficient per increase in 100 cells/ μ L, 0.0128; $p=0.03$), and lower DL_{CO} was independently associated with a history of bacterial or *Pneumocystis* pneumonia ($p=0.007$) and cocaine use ($p=0.003$), while better DL_{CO} was associated with marijuana use ($p=0.03$).

Dyspnea

Dyspnea was present in 33 (33.3%) participants and did not differ between HIV-infected and HIV-uninfected groups (34.9% vs. 30.6%, $p=0.66$). Dyspnea in HIV-infected participants was associated with pre- and post-bronchodilator airflow obstruction and presence of moderate diffusing capacity impairment ($DL_{CO} < 60\%$ predicted) and tended to be more common in those with a history of pneumonia, use of intravenous drugs, and those with higher plasma HIV RNA copy numbers. In multivariable models, moderate diffusing impairment (OR, 3.6; $p=0.03$) remained significantly associated with dyspnea.

DISCUSSION

The current study is the first to compare spirometry and diffusing capacity in a cohort of HIV-infected and HIV-uninfected women. While spirometry values were similar between HIV-infected and HIV-uninfected participants, diffusing capacity was significantly lower among women infected with HIV, independent of other contributory variables.

This study confirms the high prevalence of impaired diffusing capacity among HIV-infected persons^{3, 22}, and it is the first to report that HIV infection is an independent risk factor for impaired DL_{CO} in women. We found that the impairment in diffusing capacity is related to HIV-associated immune impairment (CD4 count < 200 cells/ μ L) independent of other covariates (including smoking). Both prior post-ART studies found a strikingly high prevalence of HIV-associated diffusing capacity impairment (42–64%)^{3, 22}, but with no comparable HIV-uninfected control group. Inclusion of HIV-uninfected participants whose demographics and risk exposures were fairly comparable to the HIV-infected participants is a particular strength of the current study.

This study also describes contributors to DL_{CO} impairment among HIV-infected women in the ART era. Pre-ART era predictors of DL_{CO} reduction among HIV-infected persons included AIDS and associated conditions²³, and in the ART era, greater cumulative smoking history and use of *Pneumocystis* prophylaxis have been associated with worse diffusing capacity³. Among HIV-infected women in the current study, the majority of whom were on ART, history of bacterial or *Pneumocystis* pneumonia and cocaine use were associated with

worse DL_{CO} . There was also a positive correlation between DL_{CO} and current CD4 cell count among HIV-infected participants, suggesting a possible role of immunosuppression.

The mechanisms of impaired diffusing capacity associated with HIV remain unclear. Low diffusing capacity may be related to emphysema, which is overall increased in HIV-infected smokers⁸. In the current study, diffusing capacity impairment was strongly associated with airflow obstruction; however, impaired diffusing capacity was frequently present without obstruction. The latter pattern may represent early emphysema, but may also represent pulmonary vascular disease, interstitial lung disease, or primary cardiac dysfunction – all of which are reported to be more common in HIV-infected persons^{2, 24–28}.

An additional novel finding of this study is the association of HCV and worse airflow obstruction in HIV-infected participants. We also report HCV to be associated with lower diffusing capacity and obstruction in the overall cohort. Previous investigations have described deleterious effects of HCV on respiratory outcomes in the general population^{29–31}, theorized to be related mechanistically to systemic and pulmonary inflammation^{30, 32–35}. The role of HCV on lung function may be important in the HIV population, as HCV/HIV co-infection is common,³⁶ and HCV viremia in the setting of HIV is associated with a state of immune activation^{37, 38}. Intravenous drug use is a potential confounder of the relationship between HCV and respiratory function that we did not find in multivariable modeling, likely because ever-use of intravenous drugs was highly prevalent in the cohort, and we could not account for other unmeasured confounders associated with intravenous drug use. Examination of the associations of HCV, intravenous drug use, the precise drug(s) injected, and respiratory outcomes in cohorts with less pervasive intravenous drug exposure may help illuminate the differential effects of each exposure on pulmonary outcomes.

To evaluate the clinical impact of pulmonary dysfunction in this cohort, we also assessed the participants' respiratory symptoms. Other ART era studies report that respiratory symptoms are common in HIV,^{3, 4, 10} and HIV is independently associated with increases in moderate dyspnea¹⁰. Although dyspnea was not more common in HIV-infected participants in our study, greater dyspnea was present in HIV-infected women with airflow obstruction and reduced DL_{CO} . These findings indicate that lung function abnormalities in HIV-infected women are not incidental findings, but are clinically relevant, with impact on symptoms and potentially quality of life⁹.

The study has several limitations. Assessment of pulmonary outcomes was cross-sectional, and therefore could not address changes in respiratory function over time. The data generated from this cohort, which has a particularly high frequency of intravenous drug use and active HCV, may not be applicable to all populations. There was also a relatively low level of cumulative cigarette smoking in this cohort, which may explain the lack of association of pulmonary function with smoking. Finally, lung volumes, which may be helpful in elucidating causes of DL_{CO} reduction, were not measured.

This study provides the first analysis of pulmonary function abnormalities in a female cohort and is the first to report HIV as an independent risk factor for DL_{CO} impairment in women. Abnormal diffusing capacity and airflow obstruction were both associated with symptoms of shortness of breath among HIV-infected women, reinforcing the clinical relevance of the findings. Pulmonary function testing has been reported to be underutilized in the HIV-infected population³, and previous studies have found that diffusing capacity abnormalities in HIV are related to emphysema, airflow obstruction, and echocardiographic evidence of pulmonary hypertension. This study provides further support for advocating appropriate diagnostic pulmonary testing, including diffusing capacity measurements, for patients with

respiratory symptoms. Future respiratory research in HIV will benefit from efforts to determine underlying causes and appropriate treatment of pulmonary dysfunction among persons with chronic HIV infection.

Acknowledgments

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group and The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt).

Source of Funding: This work was supported by the National Heart, Lung, and Blood Institute [F32 HL114426 to MF; K23 HL108697 to MG; K24 HL 087713 to LH, R01 HL083461, HL083461S, and HL090339 to AM]; the National Institute of Allergy and Infectious Diseases [U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590 to WIHS]; the Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01-HD-32632 to WIHS]; the National Cancer Institute; the National Institute on Drug Abuse; the National Institute on Deafness and Other Communication Disorders; and the National Center for Research Resources [UCSF-CTSI Grant Number UL1 RR024131 to WIHS]. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. *Chest*. 2006 Nov; 130(5):1326–1333. [PubMed: 17099007]
2. Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. *American journal of respiratory and critical care medicine*. 2011 Feb 1; 183(3):388–395. [PubMed: 20851926]
3. Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. *American journal of respiratory and critical care medicine*. 2010 Sep 15; 182(6):790–796. [PubMed: 20522793]
4. George MP, Kannass M, Huang L, Sciurba FC, Morris A. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. *PloS one*. 2009; 4(7):e6328. [PubMed: 19621086]
5. Cui Q, Carruthers S, McIvor A, Smaill F, Thabane L, Smieja M. Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. *AIDS research and therapy*. 2010; 7:6. [PubMed: 20298614]
6. Hirani A, Cavallazzi R, Vasu T, et al. Prevalence of obstructive lung disease in HIV population: a cross sectional study. *Respiratory medicine*. 2011 Nov; 105(11):1655–1661. [PubMed: 21703841]
7. CDC. HIV Surveillance --- United States: 1981–2008. *MMWR*. 2011; 60(21):689–693. [PubMed: 21637182]
8. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. *Annals of internal medicine*. 2000 Mar 7; 132(5):369–372. [PubMed: 10691587]
9. Drummond MB, Kirk GD, McCormack MC, et al. HIV and COPD: impact of risk behaviors and diseases on quality of life. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2010 Nov; 19(9):1295–1302.
10. Drummond MB, Kirk GD, Ricketts EP, et al. Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. *BMC pulmonary medicine*. 2010; 10:27. [PubMed: 20459792]
11. Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. *American journal of public health*. 2006 Jun; 96(6):1060–1065. [PubMed: 16670229]
12. Gan WQ, Man SF, Postma DS, Camp P, Sin DD. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Respiratory research*. 2006; 7:52. [PubMed: 16571126]

13. Bacon MC, von Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. *Clinical and diagnostic laboratory immunology*. 2005 Sep; 12(9):1013–1019. [PubMed: 16148165]
14. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. *Epidemiology*. 1998 Mar; 9(2):117–125. [PubMed: 9504278]
15. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). The American review of respiratory disease. 1978 Dec; 118(6 Pt 2):1–120. [PubMed: 742764]
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005 Aug; 26(2):319–338. [PubMed: 16055882]
17. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J*. 2005 Oct; 26(4):720–735. [PubMed: 16204605]
18. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *American journal of respiratory and critical care medicine*. 1999 Jan; 159(1):179–187. [PubMed: 9872837]
19. Neas LM, Schwartz J. The determinants of pulmonary diffusing capacity in a national sample of U.S. adults. *American journal of respiratory and critical care medicine*. 1996 Feb; 153(2):656–664. [PubMed: 8564114]
20. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005 Nov; 26(5):948–968. [PubMed: 16264058]
21. Hosmer DW Jr, Wang CY, Lin IC, Lemeshow S. A computer program for stepwise logistic regression using maximum likelihood estimation. *Computer programs in biomedicine*. 1978 Jun; 8(2):121–134. [PubMed: 668307]
22. Kristoffersen USLA, Mortensen J, Gerstoft J, Gutte H, Kjaer A. Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. *Clinical Physiology and Functional Imaging*. 2012
23. Rosen MJ, Lou Y, Kvale PA, et al. Pulmonary function tests in HIV-infected patients without AIDS. Pulmonary Complications of HIV Infection Study Group. *American journal of respiratory and critical care medicine*. 1995 Aug; 152(2):738–745. [PubMed: 7633736]
24. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. *Chest*. 1991 Nov; 100(5):1268–1271. [PubMed: 1935280]
25. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *American journal of respiratory and critical care medicine*. 2008 Jan 1; 177(1):108–113. [PubMed: 17932378]
26. Hsue PY, Hunt PW, Ho JE, et al. Impact of HIV infection on diastolic function and left ventricular mass. *Circulation*. 2010 Jan; 121(1):132–139. [PubMed: 19933410]
27. Mondy KE, Gottdiener J, Overton ET, et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2011 Feb 1; 52(3):378–386. [PubMed: 21217185]
28. Morris A, Gingo MR, George MP, et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. *AIDS (London, England)*. 2012 Mar 27; 26(6):731–740.
29. Silva DR, Stiff J, Cheinquer H, Knorst MM. Prevalence of hepatitis C virus infection in patients with COPD. *Epidemiology and infection*. 2010 Feb; 138(2):167–173. [PubMed: 19563696]
30. Kanazawa H, Mamoto T, Hirata K, Yoshikawa J. Interferon therapy induces the improvement of lung function by inhaled corticosteroid therapy in asthmatic patients with chronic hepatitis C virus infection: a preliminary study. *Chest*. 2003 Feb; 123(2):600–603. [PubMed: 12576385]
31. Kanazawa H, Yoshikawa J. Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. *The American journal of medicine*. 2004 Jun 1; 116(11):749–752. [PubMed: 15144911]
32. Idilman R, Cetinkaya H, Savas I, et al. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C. *Journal of medical virology*. 2002 Jan; 66(1):34–39. [PubMed: 11748656]
33. Kubo K, Yamaguchi S, Fujimoto K, et al. Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection. *Thorax*. 1996 Mar; 51(3):312–314. [PubMed: 8779138]

34. Yamaguchi S, Kubo K, Fujimoto K, Honda T, Sekiguchi M, Sodeyama T. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha. *Thorax*. 1997 Jan; 52(1):33–37. [PubMed: 9039237]
35. Kanazawa H, Yoshikawa J. Alterations in T-lymphocyte subsets in the airways of asthmatic patients with active hepatitis C virus infection. *Respiration, international review of thoracic diseases*. 2006; 73(3):318–323. [PubMed: 16179822]
36. Sherman KE, Rouster SD, Chung RT, Rajcic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2002 Mar 15; 34(6):831–837. [PubMed: 11833007]
37. Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfecting with hepatitis C virus. *The Journal of infectious diseases*. 2010 Mar 15; 201(6):823–834. [PubMed: 20151840]
38. Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 counts associated with Hepatitis C Infection in HIV-1 Natural Viral Suppressors. *AIDS (London, England)*. 2012 Jul 20.

Table 1

Participant characteristics by HIV status

	HIV-infected (n=63)	HIV-uninfected (n=36)	p-value
Age, mean years (SD)	49.1 (8.9)	43.7 (9.3)	0.005
African-American, n (%)	41 (65.1)	24 (66.7)	0.87
Hispanic, n (%)	4 (6.4)	4 (11.1)	0.46
Smoking status, n (%)			0.10
Never	16 (25.4)	14 (38.9)	
Former	18 (28.6)	4 (11.1)	
Current	29 (46.0)	18 (50.0)	
Pack-years smoking, median (range)	10.0 (0–78)	4.2 (0–38)	0.054
Alcohol use, any, n (%)	25 (39.7)	20 (55.6)	0.13
Heavy alcohol use, n (%)	9 (14.3)	6 (16.7)	0.75
Marijuana smoking, n (%)			
In the past 6 months	16 (25.4)	11 (30.6)	0.58
Ever	52 (82.5)	31 (86.1)	0.64
Cocaine use, n (%)			
In the past 6 months	1 (1.6)	2 (5.6)	0.30
During study enrollment	23 (36.5)	18 (50.0)	0.19
Intravenous drug use, n (%)			
In the past 6 months	6 (9.5)	2 (5.6)	0.49
Ever	34 (54.0)	11 (30.6)	0.02
Illicit drug use in the past 6 months, n (%)	25 (39.7)	14 (38.9)	0.94
Bacterial pneumonia, ever, n (%)	11 (17.5)	4 (11.8)	0.72
<i>Pneumocystis</i> pneumonia, ever, n (%)	4 (6.4)	0	--
Hepatitis C RNA positive, n (%)	21 (33.3)	6 (16.7)	0.07
Currently on HAART, n (%)	51 (81.0)		
CD4 T-cell counts			
Within past 6 months, median (range)	426 (3–1220)		
Nadir during study, median (range)	159 (0–797)		
Mean during study, median (range)	392 (68–1214)		
Plasma HIV RNA level (log copies/mL), median (range)	4.6 (3.9–12.2)		
Pre-BD FEV ₁ % predicted, mean (SD)	97.0 (15.1)	92.4 (12.1)	0.12
Pre-BD FVC % predicted, mean (SD)	106.1 (15.5)	101.2 (14.5)	0.13
Pre-BD FEV ₁ /FVC, mean (SD)	0.74 (0.08)	0.75 (0.08)	0.48
Post-BD FEV ₁ % predicted, mean (SD)	101.9 (14.2)	97.6 (12.9)	0.14
Post -BD FVC % predicted, mean (SD)	104.9 (15.2)	101.3 (14.8)	0.26
Post -BD FEV ₁ /FVC, mean (SD)	0.78 (0.07)	0.79 (0.08)	0.62
DL _{CO} % predicted, mean (SD)	65.5 (13.7)	72.7 (13.3)	0.01

BD – bronchodilator; DL_{CO} – diffusing capacity for carbon monoxide; FEV₁ – forced expiratory volume in the first second; FVC – forced vital capacity; HIV – human immunodeficiency virus; n – number; SD – standard deviation; RNA – ribonucleic acid

Table 2

Multivariable regression for factors independently associated with pulmonary function in the entire cohort (HIV-infected and HIV-uninfected)

	Linear regression	coefficient	p-value
Pre-BD FEV ₁ % predicted	Hepatitis C RNA positive	-0.0678	0.03
Pre-BD FEV ₁ /FVC	Age at visit (per year)	-0.0028	0.001
Post-BD FEV ₁ % predicted	Hepatitis C RNA positive	-0.0867	0.005
Post-BD FEV ₁ /FVC	Age at visit (per year)	-0.0028	<0.001
	Pack-years smoking (per 10)	-0.0108	0.04
DL _{CO} % predicted	HIV infection	-0.0586	0.03
	Hepatitis C RNA positive	-0.0812	0.009
B. Multivariable regression for factors independently associated with pulmonary function in HIV-infected participants only			
	Linear regression	coefficient	p-value
Pre-BD FVC % predicted	Marijuana use (ever)	0.1027	0.045
Pre-BD FEV ₁ /FVC	History of bacterial or <i>Pneumocystis</i> pneumonia	-0.0613	0.01
Post-BD FEV ₁ % predicted	Marijuana use (ever)	0.0999	0.03
	Hepatitis C RNA positive	-0.0799	0.03
Post-BD FVC % predicted	Hepatitis C RNA positive	-0.0851	0.04
Post-BD FEV ₁ /FVC	History of bacterial or <i>Pneumocystis</i> pneumonia	-0.0482	0.03
	Age at visit (per year)	-0.0021	0.04
DLco % predicted	History of bacterial or <i>Pneumocystis</i> pneumonia	-0.1026	0.007
	Cocaine use (during enrollment)	-0.0968	0.003
	Marijuana use (ever)	0.0930	0.03

BD – bronchodilator; DLco - diffusing capacity for carbon monoxide; FEV₁ - forced expiratory volume in the first second; FVC - forced vital capacity